MedTrace Logo

Prevenar13 Drug Use Investigation - Adults Aged 65 Years or Older-

NCT03014206 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 696

Last updated 2023-09-13

Study results available
· View outcomes & findings →

Summary

This study aims to understand the following items in post-marketing actual clinical settings to evaluate the safety of 13vPnC administered as a single dose in the elderly (adults aged 65 years or older).

1. To confirm the use in actual clinical settings
2. To confirm the occurrence of adverse events

Conditions

  • Adult Not Younger Than 65 Years

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-15
Primary Completion
2017-01-31
Completion
2017-01-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03014206 on ClinicalTrials.gov